TYK352: Difference between revisions
m 1 revision imported |
m Text replacement - "<p style="text-align: center;"> About Test Your Knowledge</p>" to "<p style="text-align: center;"> About Test Your Knowledge</p> Category:TYK" |
||
| (One intermediate revision by the same user not shown) | |||
| Line 27: | Line 27: | ||
<p style="text-align: center;">[[TYK351|<Prev Question]] --- [[TYK353|Next Question>]]</p> | <p style="text-align: center;">[[TYK351|<Prev Question]] --- [[TYK353|Next Question>]]</p> | ||
<p style="text-align: center;">[[TYK About | About Test Your Knowledge]]</p> | <p style="text-align: center;">[[TYK About | About Test Your Knowledge]]</p> | ||
[[Category:TYK]] | |||
[[Category:TYK]] | |||
Latest revision as of 02:35, 25 September 2026
What is the most significant risk factor for cardiotoxicity from doxorubicin?
a) Dose of Doxorubicin
b) Duration of therapy
c) Family history
d) Patient age
Click for Answer
Answer
Answer a. Anthracycline cardiotoxicity is a lifetime cumulative dose-related side effect. Total lifetime dose should be monitored. In addition, serial echocardiography is important to monitor for cardiotoxicity, which may occur years following therapy.
Notes
- This question originally printed in the Pediatric Anesthesiology Review Topics kindle book series, and appears courtesy of Naerthwyn Press, LLC.